Interstitial Lung Disease Market

Interstitial Lung Disease (ILD) Insights and Trends

• According to DelveInsight’s analysis, ILD market size was found to be more than USD 6 billion in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• ILD reported approximately 500,000 diagnosed prevalent cases in the US in 2025 and this number is projected to increase by 2036.
• Limited disease-modifying options for several ILD subtypes, with current therapies largely slowing progression rather than reversing fibrosis, constrain clinical outcomes and long-term treatment effectiveness.
• Strong uptake of premium and differentiated therapies, particularly antifibrotics and pulmonary hypertension–targeted agents (e.g., OFEV, TYVASO/TYVASO DPI), is driving revenue growth beyond prevalence expansion.
• The emerging ILD pipeline is robust and highly diversified, encompassing novel antifibrotic, immunomodulatory, and lung-targeted delivery approaches aimed at improving efficacy, tolerability, and phenotype specificity. Notable late- and mid-stage candidates include taladegib (ENV-101), admilparant (BMS-986278), and seralutinib, alongside immune-modulating agents such as belimumab (BENLYSTA) and efzofitimod. Advanced inhaled and localized platforms—Treprostinil Palmitil Inhalation Powder (TPIP), L606, and AP01 (inhaled pirfenidone)—seek to maximize pulmonary exposure while limiting systemic toxicity, while innovative approaches such as N115 (nonsteroidal nasal spray) further expand mechanistic diversity ILD is more prevalent in men than in women.
• Shift toward long-term disease management, with chronic therapy use, combination approaches, and extended treatment duration, is increasing per-patient lifetime value, especially in progressive fibrosing ILD.
• Currently approved antifibrotic therapies are associated with significant gastrointestinal, hepatic, and tolerability-related adverse effects, often leading to dose reductions or discontinuation. Chronic daily oral dosing over years further compounds adherence challenges, particularly in elderly patients or those with comorbid autoimmune disease. Even inhaled prostacyclin therapies used in ILD-associated pulmonary hypertension, such as TYVASO, impose device-dependent administration burdens.

Interstitial Lung Disease (ILD) Market size and forecast

• 2025 Interstitial Lung Disease (ILD) Market Size: USD ~6 billion
• 2036 Projected Interstitial Lung Disease (ILD) Market Size: USD ~13 billion
• Interstitial Lung Disease (ILD) Growth Rate (2026–2036): 8.7% CAGR

DelveInsight's ‘Interstitial Lung Disease (ILD) – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of ILD, historical and forecasted epidemiology, as well as the ILD market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The ILD market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, ILD patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2026–2036) across global regions. The report highlights key unmet medical needs in ILD and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, Spain and the UK
• Asia-Pacific: Japan

Interstitial Lung Disease (ILD) Understanding and Treatment Algorithm

Interstitial Lung Disease (ILD) Overview and Diagnosis

ILD, also known as diffuse parenchymal lung diseases, represents a heterogeneous group of lung disorders characterized by shared clinical, radiographic, physiologic, or pathologic features. Understanding ILD is challenging due to complex terminology and broad disease diversity. Pathologically, these conditions involve inflammatory and fibrotic processes that extend beyond the interstitium to affect the lung parenchyma, including alveoli, alveolar ducts, and bronchioles.

The diagnosis of ILD requires a comprehensive and multidisciplinary approach, as ILD encompasses a broad and heterogeneous group of disorders with overlapping clinical, radiologic, and histopathologic features. Rather than relying on a single test, diagnosis is achieved through the integration of clinical history, physiologic assessment, imaging, laboratory evaluation, and, when necessary, tissue sampling, with the ultimate goal of identifying the underlying disease process and defining disease behavior.

Further details are provided in the report.

Current Interstitial Lung Disease (ILD) Treatment Landscape

The ILD treatment pipeline appears robust, with several therapies expected to launch during the forecast period. These include belimumab (BENLYSTA), treprostinil palmitil inhalation powder (TPIP), seralutinib, L606, admilparant (BMS-986278), N-115 and others.

Long-term market growth will depend on payer recognition of clinical value, as reimbursement decisions increasingly rely on demonstrated reduction in proteinuria, delayed progression to end-stage kidney disease, and real-world safety outcomes.

Further details related to country-based variations are provided in the report.

Interstitial Lung Disease (ILD) Unmet Needs

The section “unmet needs of ILD” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

• Limited Disease-Modifying Options Beyond Slowing Fibrosis
• High Treatment Burden and Poor Long-Term Tolerability
• Inadequate Stratification Across Heterogeneous ILD Subtypes
• Lack of Noninvasive Biomarkers for Early Diagnosis and Monitoring

and others…..

Note: Comprehensive unmet needs insights in ILD and their strategic implications are provided in the full report.

Interstitial Lung Disease (ILD) Epidemiology

Key Findings from Interstitial Lung Disease (ILD) Epidemiological Analysis and Forecast

• The total number of diagnosed prevalent cases of ILD in the 7MM is ~1.3 million in 2025.
• According to DelveInsight’s estimates, in 2025, the US reported nearly 520,000 diagnosed prevalent cases of ILD.
• According to DelveInsight analysis, in 2025, males represented about 44% of ILD cases in the US, whereas females accounted for roughly 56%.
• In 2025, sarcoidosis represented the most prevalent ILD subtype across EU4 and the UK, accounting for the largest share of diagnosed patients with approximately 180,000 cases, highlighting the significant contribution of inflammatory and immune-mediated lung disease to the regional ILD burden. This was followed by IPF with about 120,000 patients, underscoring the continued clinical and healthcare impact of progressive fibrotic ILD.
• DelveInsight’s 2025 assessment highlights a modest gender disparity in ILD in Japan, with males accounting for approximately 52% of cases and females comprising about 48%. This near-balanced distribution suggests that while ILD slightly predominates in men—potentially reflecting higher exposure to occupational or environmental risk factors—the disease burden remains substantial in women, underscoring the need for gender-inclusive awareness, diagnosis, and management strategies.
• The number of treated ILD cases in the United States was about 420,000 in 2025 and is projected to increase by 2036.This upward trend highlights a steadily expanding treated population, reflecting both a rising underlying disease burden and improvements in diagnosis, treatment initiation, and long-term disease management across the US healthcare system.

Interstitial Lung Disease (ILD) Drug Analysis & Competitive Landscape

The ILD drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the ILD treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the ILD therapeutics market.

Approved Therapies for ILD

Treprostinil (TYVASO/TYVASO DPI/TREPROST): United Therapeutics

TYVASO and treprostinil (TYVASO DPI) are inhaled prescription therapies for adults with PAH (Group 1) and PH-ILD (Group 3). As a prostacyclin analogue, treprostinil promotes pulmonary vasodilation and inhibits platelet aggregation, improving exercise capacity.

United Therapeutics reported in March 2026 that the Phase III TETON-1 trial assessing inhaled treprostinil achieved its primary endpoint in patients with idiopathic pulmonary fibrosis (IPF), indicating a notable improvement in lung function (FVC) and supporting the drug's potential to extend beyond PH-ILD into more general ILD indications.

Positive outcomes from the Phase III TETON-2 trial in 2025 further demonstrated the safety and effectiveness of inhaled treprostinil in ILD, with steady improvements in lung function and no new safety signals, setting up the treatment for possible regulatory submission in populations with IPF and progressive fibrosing ILD.

Interstitial Lung Disease (ILD) Pipeline Analysis

Belimumab (BENLYSTA): GSK

Belimumab (BENLYSTA) is a B-lymphocyte Stimulator (BLyS)-specific inhibitor that binds to soluble BLyS, a key survival factor for B cells. As a fully human monoclonal antibody (mAb), belimumab inhibits BLyS-mediated prolonged B-cell survival, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.

Belimumab (BENLYSTA) is currently under evaluation in late-stage (Phase II/III and Phase III) clinical trials for the treatment of SSc-ILD , and CTD-ILD reflecting increasing interest in B-cell-targeted immunomodulation to preserve lung function and slow fibrotic disease progression.

• In February 2023, GSK announced that the US FDA has granted orphan drug designation (ODD) to Belimumab (BENLYSTA), a B-cell–inhibiting monoclonal antibody, for the potential treatment of systemic sclerosis.

ILD Key Players, Market Leaders and Emerging Companies

• United Therapeutics
• Liquidia Corporation
• Boehringer Ingelheim
• Roche
• Insmed
• GSK and others

Interstitial Lung Disease (ILD) Drug Updates

• In December 2025, PureTech Health announced the successful completion of the End-of-Phase II (EOP2) meeting with the US FDA regarding the development of deupirfenidone (LYT-100) for the treatment of IPF.
• In December 2025, US FDA approved nerandomilast (JASCAYD) tablets for the treatment of PPF in adults.
• In November 2025, Endeavor BioMedicines reported that the EMA granted PRIME designation to its investigational therapy taladegib for the treatment of IPF.

Interstitial Lung Disease (ILD) Market Outlook

The expanding ILD market is complemented by widely used supportive and background therapies, including corticosteroids, immunosuppressants, biologics, and adjunctive agents such as cough suppressants. In parallel, the emergence of next-generation pipeline therapies—including seralutinib, L606, N-115, efzofitimod—is broadening the therapeutic landscape by targeting diverse disease mechanisms, sustaining long-term market growth and treatment innovation.

Key marketed therapies shaping current management

Nerandomilast (JASCAYD): An oral, small-molecule therapy developed by Boehringer Ingelheim, is an oral phosphodiesterase-4 inhibitor approved in the US in December 2025, expanding the anti-fibrotic treatment landscape. By modulating intracellular inflammatory and fibrotic signaling pathways, nerandomilast provides an additional oral disease-modifying option for patients with chronic fibrosing ILD. Its introduction reflects ongoing efforts to diversify therapeutic mechanisms beyond tyrosine kinase inhibition.

Nintedanib capsules (OFEV): An oral tyrosine kinase inhibitor (TKI) that targets key pathways driving lung fibrosis, helping slow lung function decline. It is approved for IPF, systemic sclerosis-associated ILD, and other chronic fibrosing ILDs with a progressive phenotype. In March 2025, Sandoz reported that it reached a federal court consent judgment with Boehringer Ingelheim allowing its proposed generic nintedanib capsules (100 mg and 150 mg) to proceed without infringing key OFEV patents, potentially accelerating US generic competition.

And more

Overall, the launch of first-in-class therapies, improved testing, and rising disease awareness are expected to drive steady growth in the 7MM ILD market from 2022–2036, with strong commercial implications for both marketed products and emerging pipelines. As diagnostic sophistication improves — driven by HRCT, multidisciplinary consensus, and broader awareness — the pool of patients recognized with PF-ILD has expanded beyond traditional IPF. This expansion, coupled with unmet needs in disease modification and quality-of-life preservation, makes ILD a strategically important specialty market with evolving treatment paradigms and high per-patient value.

• Among the 7MM, the US accounted for the largest market size of ILD. i.e., USD ~ 5 billion in 2025.
• Japan’s ILD market exceeded USD 350 million in 2025 and is projected to grow further through 2036, driven by rising treatment adoption and the expected introduction of emerging therapies.
• In 2036, among all the therapies for ILD, the highest revenue is estimated to be generated by JASCAYD (nerandomilast tablets) in the 7MM.
• The ILD therapeutic pipeline is undergoing a decisive shift from conventional anti-fibrotic and broad immunosuppressive strategies toward targeted biologics, novel small molecules, and advanced inhaled delivery platforms. Several late- and mid-stage programs now aim to address immune dysregulation, fibrotic signaling, and pulmonary vascular remodeling in a more mechanistically precise manner. BENLYSTA (Belimumab), developed by GSK, represents a shift toward B-cell-targeted therapy in autoimmune-driven interstitial lung disease, particularly systemic sclerosis–associated and connective tissue disease–associated ILD.

Further details will be provided in the report…..

Drug Class/Insights into Leading Emerging and Marketed Therapies in Interstitial Lung Disease (ILD) (2026–2036 Forecast)

Corticosteroids and immunosuppressive agents: Many patients are initially treated with corticosteroids, such as prednisone. In selected cases—particularly when ILD is associated with inflammatory or autoimmune processes—additional immunosuppressive agents may be used. These therapies can help slow disease progression in certain ILD subtypes.

Antifibrotic therapies: Pirfenidone and nintedanib have demonstrated the ability to slow functional decline in IPF. Nintedanib is also approved for use in progressive fibrosing ILDs of other etiologies. Both agents are commonly associated with adverse effects, making individualized risk–benefit assessment essential.

Acid suppression therapies: Gastroesophageal reflux disease is frequently observed in IPF and has been associated with increased lung injury. In patients with symptomatic reflux, acid-suppressive medications may be considered to mitigate potential pulmonary impact.

Interstitial Lung Disease (ILD) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the ILD drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The total market size of the ILD is anticipated to experience growth during the forecast period due to promising emerging treatment options that include admilparant (BMS-986278), seralutinib, L606, treprostinil palmitil inhalation powder (TPIP) and others.

Emerging clinical and market trends

Broadening spectrum of diagnosed diseases

Progressive fibrosing ILD across multiple subtypes is expanding treatment beyond IPF, with agents such as nintedanib now used in PF-ILD and CTD-ILD.

Earlier and more precise diagnosis

HRCT and AI-supported imaging are enabling earlier detection, supporting the timely initiation of anti-fibrotics and immunomodulators.

Phenotype-driven therapeutics

Autoimmune-predominant ILD is advancing toward targeted immunotherapies such as belimumab, while fibrotic-predominant disease remains anchored by nintedanib and pirfenidone.

Inhaled delivery renaissance

Localized lung delivery is expanding with inhaled treprostinil and next-generation inhaled anti-fibrotic candidates.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Interstitial Lung Disease (ILD) 

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

EU4 and the UK

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report….

Interstitial Lung Disease (ILD) therapies Price Scenario & Trends

Pricing and analogue assessment of ILD therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Pricing of ILD Approved Drugs

OFEV treatment cost was evaluated using the approved dosing regimen of 150 mg administered orally twice daily with food. Under this standardized assumption, the annual treatment cost in the US was estimated nearly USD 160,000, reflecting prevailing list pricing. In Germany, pricing based on the Gemeinsamer Bundesausschuss (G-BA) framework yielded an annual cost around USD 41,938, while in the United Kingdom, NICE-aligned pricing resulted in an annual treatment cost nearly USD 35,000.

Industry Experts and Physician Views for Interstitial Lung Disease (ILD)

To keep up with ILD market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the ILD’s emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in ILD, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 8+ KOLs to gather insights at country level. Centers such as the University of Alabama, University Hospital Heidelberg, Keio University Hospital, and Hannover Medical School etc. were contacted.

Their opinion helps understand and validate current and emerging ILD therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in ILD.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of ILD, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of ILD, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the ILD market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM ILD market.

Report Insights

• Interstitial Lung Disease (ILD) Patient population forecast
• Interstitial Lung Disease (ILD) therapeutics market size
• Interstitial Lung Disease (ILD) pipeline analysis
• Interstitial Lung Disease (ILD) market size and trends
• Interstitial Lung Disease (ILD) market opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) bottom‑up forecasting
• Artificial Intelligence (AI)-enabled market research report
• 11-year forecast
• Interstitial Lung Disease (ILD) market outlook (North America, Europe, Asia-Pacific)
• Patient Burden trends (by geography)
• Interstitial Lung Disease (ILD) Treatment addressable Market (TAM)
• Interstitial Lung Disease (ILD) Competitive Landscape
• Interstitial Lung Disease (ILD) major companies Insights
• Interstitial Lung Disease (ILD) Price trends and analogue assessment
• Interstitial Lung Disease (ILD) Therapies Drug Adoption/Uptake
• Interstitial Lung Disease (ILD) Therapies Peak Patient Share analysis

Report Assessment

• Interstitial Lung Disease (ILD) Current treatment practices
• Interstitial Lung Disease (ILD) Unmet needs
• Interstitial Lung Disease (ILD) Clinical development Analysis
• Interstitial Lung Disease (ILD) emerging drugs product profiles
• Interstitial Lung Disease (ILD) Market attractiveness
• Interstitial Lung Disease (ILD) Qualitative analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the ILD market size, the market size by therapies, market share (%) distribution in 2026, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of ILD?
• What are the disease risks, burdens, and unmet needs of ILD? What will be the growth opportunities across the 7MM concerning the patient population with ILD?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of ILD? What are the current guidelines for treating ILD in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the ILD market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)  enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.